Medical Use
Fasenra is a monoclonal antibody (IgG1, kappa) that targets the interleukin-5 receptor alpha and is used as an add-on maintenance treatment for patients aged 12 and older with severe asthma and an eosinophilic phenotype.
Limitations of Use: Fasenra is not intended for the treatment of other eosinophilic conditions and is not suitable for relieving acute bronchospasm or status asthmaticus.
Recommended Dosage: Fasenra is administered via subcutaneous injection. The recommended dosage is 30 mg every four weeks for the first three doses, followed by 30 mg every eight weeks. Injections should be given in the upper arm, thigh, or abdomen.
A healthcare professional should administer the injection, and patients should be monitored post-administration as per clinical practice guidelines.
Before use, allow Fasenra to reach room temperature by leaving the carton out for about 30 minutes. The injection should be administered within 24 hours or disposed of in a sharps container.
Warning & Precautions
Use of Fasenra Injection: The 30 mg/mL solution in a single-dose prefilled syringe for subcutaneous use is contraindicated in individuals with known hypersensitivity to benralizumab or any of its components.
Hypersensitivity reactions, such as rash, anaphylaxis, angioedema, and urticaria, may occur after using Fasenra 30 mg/mL. These reactions typically occur within hours but can sometimes be delayed by days. If a hypersensitivity reaction occurs, discontinue treatment immediately.
Benralizumab should not be used to treat acute asthma symptoms or exacerbations, nor should it be used for acute bronchospasm or status asthmaticus. Patients should seek medical advice if their asthma remains uncontrolled or worsens after starting benralizumab therapy.
Do not abruptly stop systemic or inhaled corticosteroids when starting Fasenra. Any reduction in corticosteroid dosage should be gradual and supervised by a doctor, as abrupt changes can cause withdrawal symptoms or reveal conditions previously controlled by corticosteroid therapy.
Eosinophils, also known as eosinophiles or acidophils, play a role in the immune response to certain helminth infections. Patients with known helminth infections were excluded from clinical trials, and it is unclear if benralizumab affects the response to these infections.
Patients with pre-existing helminth infections should be treated before starting Fasenra. If a patient becomes infected while on Fasenra and does not respond to anti-helminth treatment, discontinue Fasenra until the infection is resolved.
Documentation Availability
Documents required to import FASENRA to India?
FASENRA (benralizumab) injection can be imported by patients or treating physicians on behalf of patients. The following documentation is required to import the product:
- (i)2 ID proofs along with PAN card details along with attested scanned copies
- (ii)Valid doctor prescription scanned copy
- (iii)Doctor’s MCI number
- (iv)Doctor’s mobile number
- (v)Patients diagnostic reports
How is the order confirmed?
The order will be confirmed only after the receipt of:
- (i)The above-mentioned documents and drug availability.
- (ii)Import permit if applicable.
Sourcing & Delivery
The Rx4U team has extensive experience in sourcing FASENRA (Cancer Treatment Medicines) from around the world, ensuring global access to the best available treatments for our customers. We are dedicated to promptly dispensing any valid prescription. All prescriptions are verified and dispatched directly to the patient’s address. Our patients are our top priority, and we strive to improve their lives through our services.
FAQ
What is the generic name for the trade name drug Fasenra®?
The generic name for Fasenra® is Benralizumab.
Who manufactures Fasenra®?
Fasenra® is manufactured by AstraZeneca.
Is Fasenra® approved by the FDA?
Yes, Fasenra® was approved by the FDA on November 14, 2017.
Where can I get Fasenra® at the best price in India?
For the best price on Fasenra® in India, contact Rx4u team.
What dosage form is Fasenra® available in?
Fasenra® is available as a 30 mg/mL solution in a single-dose prefilled syringe for subcutaneous injection.
What are the most common side effects of Fasenra®?
The most common side effects of Fasenra® include headache and pharyngitis.
What are the storage conditions for Fasenra®?
Store Fasenra® in its original carton at 2°C to 8°C (36°F to 46°F) to protect it from light. Do not freeze or shake the medication.
Is it safe to buy Fasenra® online from India?
Yes, you can safely purchase Fasenra®online in India through https://rx4u.in/.
*Disclaimer
All Trademarks and Brands that appear on the website belong to their respective owners and Rx4U does not lay any claim on them we only provide Information.
